159 related articles for article (PubMed ID: 14602752)
21. Comparison of parathyroid hormone (1-34) and elcatonin in postmenopausal women with osteoporosis: an 18-month randomized, multicenter controlled trial in China.
Li Y; Xuan M; Wang B; Yang J; Zhang H; Zhang XZ; Guo XH; Lü XF; Xue QY; Yang GY; Ji QH; Liu ZM; Li CJ; Wu TF; Sheng ZY; Li PQ; Tong JC
Chin Med J (Engl); 2013 Feb; 126(3):457-63. PubMed ID: 23422107
[TBL] [Abstract][Full Text] [Related]
22. A comparison of parathyroid hormone-related protein (1-36) and parathyroid hormone (1-34) on markers of bone turnover and bone density in postmenopausal women: the PrOP study.
Horwitz MJ; Augustine M; Khan L; Martin E; Oakley CC; Carneiro RM; Tedesco MB; Laslavic A; Sereika SM; Bisello A; Garcia-Ocaña A; Gundberg CM; Cauley JA; Stewart AF
J Bone Miner Res; 2013 Nov; 28(11):2266-76. PubMed ID: 23661240
[TBL] [Abstract][Full Text] [Related]
23. Treatment of skeletally mature ovariectomized rhesus monkeys with PTH(1-84) for 16 months increases bone formation and density and improves trabecular architecture and biomechanical properties at the lumbar spine.
Fox J; Miller MA; Newman MK; Turner CH; Recker RR; Smith SY
J Bone Miner Res; 2007 Feb; 22(2):260-73. PubMed ID: 17087625
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis.
Henriksen K; Andersen JR; Riis BJ; Mehta N; Tavakkol R; Alexandersen P; Byrjalsen I; Valter I; Nedergaard BS; Teglbjaerg CS; Stern W; Sturmer A; Mitta S; Nino AJ; Fitzpatrick LA; Christiansen C; Karsdal MA
Bone; 2013 Mar; 53(1):160-6. PubMed ID: 23234813
[TBL] [Abstract][Full Text] [Related]
25. A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis.
Body JJ; Gaich GA; Scheele WH; Kulkarni PM; Miller PD; Peretz A; Dore RK; Correa-Rotter R; Papaioannou A; Cumming DC; Hodsman AB
J Clin Endocrinol Metab; 2002 Oct; 87(10):4528-35. PubMed ID: 12364430
[TBL] [Abstract][Full Text] [Related]
26. Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.
Gallagher JC; Rosen CJ; Chen P; Misurski DA; Marcus R
Bone; 2006 Dec; 39(6):1268-75. PubMed ID: 16884968
[TBL] [Abstract][Full Text] [Related]
27. [Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].
Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harpe K
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):269-73. PubMed ID: 15059505
[TBL] [Abstract][Full Text] [Related]
28. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
Barone A; Giusti A; Pioli G; Girasole G; Razzano M; Pizzonia M; Palummeri E; Bianchi G
J Am Geriatr Soc; 2007 May; 55(5):752-7. PubMed ID: 17493196
[TBL] [Abstract][Full Text] [Related]
29. [Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].
Jiang Y; Li M; Xia W; Xing X; Yu W; Tian J; Meng X; Zhou X
Zhonghua Yi Xue Za Zhi; 2002 Sep; 82(18):1254-6. PubMed ID: 12425805
[TBL] [Abstract][Full Text] [Related]
30. Relationship between increased endogenous parathormone levels and bone density in postmenopausal women treated with bisphosphonates.
Coin A; Veronese N; Bolzetta F; De Rui M; Manzato E; Sergi G
Panminerva Med; 2012 Dec; 54(4):277-82. PubMed ID: 23123579
[TBL] [Abstract][Full Text] [Related]
31. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers.
Kurland ES; Cosman F; McMahon DJ; Rosen CJ; Lindsay R; Bilezikian JP
J Clin Endocrinol Metab; 2000 Sep; 85(9):3069-76. PubMed ID: 10999788
[TBL] [Abstract][Full Text] [Related]
32. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective.
Boonen S; Marin F; Mellstrom D; Xie L; Desaiah D; Krege JH; Rosen CJ
J Am Geriatr Soc; 2006 May; 54(5):782-9. PubMed ID: 16696744
[TBL] [Abstract][Full Text] [Related]
33. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
Garnero P; Sornay-Rendu E; Chapuy MC; Delmas PD
J Bone Miner Res; 1996 Mar; 11(3):337-49. PubMed ID: 8852944
[TBL] [Abstract][Full Text] [Related]
34. Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss.
Gallagher JC; Fowler SE; Detter JR; Sherman SS
J Clin Endocrinol Metab; 2001 Aug; 86(8):3618-28. PubMed ID: 11502787
[TBL] [Abstract][Full Text] [Related]
35. Daily nasal spray of hPTH(1-34) for 3 months increases bone mass in osteoporotic subjects: a pilot study.
Matsumoto T; Shiraki M; Hagino H; Iinuma H; Nakamura T
Osteoporos Int; 2006 Oct; 17(10):1532-8. PubMed ID: 16767525
[TBL] [Abstract][Full Text] [Related]
36. A new active vitamin D, ED-71, increases bone mass in osteoporotic patients under vitamin D supplementation: a randomized, double-blind, placebo-controlled clinical trial.
Matsumoto T; Miki T; Hagino H; Sugimoto T; Okamoto S; Hirota T; Tanigawara Y; Hayashi Y; Fukunaga M; Shiraki M; Nakamura T
J Clin Endocrinol Metab; 2005 Sep; 90(9):5031-6. PubMed ID: 15972580
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
Schnitzer T; Bone HG; Crepaldi G; Adami S; McClung M; Kiel D; Felsenberg D; Recker RR; Tonino RP; Roux C; Pinchera A; Foldes AJ; Greenspan SL; Levine MA; Emkey R; Santora AC; Kaur A; Thompson DE; Yates J; Orloff JJ
Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
[TBL] [Abstract][Full Text] [Related]
38. A global study of vitamin D status and parathyroid function in postmenopausal women with osteoporosis: baseline data from the multiple outcomes of raloxifene evaluation clinical trial.
Lips P; Duong T; Oleksik A; Black D; Cummings S; Cox D; Nickelsen T
J Clin Endocrinol Metab; 2001 Mar; 86(3):1212-21. PubMed ID: 11238511
[TBL] [Abstract][Full Text] [Related]
39. Relationship between nutritional profile, measures of adiposity, and bone mineral density in postmenopausal Saudi women.
Alissa EM; Alnahdi WA; Alama N; Ferns GA
J Am Coll Nutr; 2014; 33(3):206-14. PubMed ID: 24869980
[TBL] [Abstract][Full Text] [Related]
40. Full length parathyroid hormone, PTH(1-84), for the treatment of severe osteoporosis in postmenopausal women.
Adami S
Curr Med Res Opin; 2008 Nov; 24(11):3259-74. PubMed ID: 18940041
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
